A phase II study of biweekly administration of paclitaxel in patients with recurrent epithelial ovarian cancer.
The purpose of this study was to assess the efficacy and toxicity of single agent paclitaxel administered biweekly to patients with relapse of epithelial ovarian cancer previously treated with platinum-based regimen. Forty patients received an initial paclitaxel dose of 134 mg/m2 administered intravenously over three hours every two weeks. 283 cycles were given. All 40 patients were evaluable for toxicity, which mainly consisted of granulocytopenia, myalgia/arthralgia, and peripheral neuropathy. Two patients developed severe hypersensitivity reactions. Dose escalation was possible by one level in 11 patients and by two levels in 12 patients, dose reductions were not necessary. Thirty-five patients were evaluated for response. Five obtained complete response (14%), eight obtained partial response (23%), and nine had stable disease (26%), while 11 patients showed progression (31%). The overall response rate was 37% (95% confidence interval 22-57%). The median duration of responses (complete and partial) was six months. Overall median time to progression and overall median survival for eligible patients (n = 35) was 4.3 months and 11 months, respectively. We conclude that biweekly administration of paclitaxel in recurrent epithelial ovarian carcinoma was active with manageable toxicity.
Departments of Obstetrics & Gynecology, Trondheim University Hospital, Trondheim, and Tromsø University Hospital, Tromsø, and Bristol-Myers Squibb Norway Ltd., Oslo, Norway.
E.
E
Lorenz
B.
B
Hagen
A.
A
Himmelmann
K.
K
Kjørstad
M.
M
Onsrud
S.
S
Tingulstad
G.
G
Gundersen